The United States Advisory Committee on Immunization Practices recommends that US residents aged ≥6 months receive annual influenza vaccination by October of each year to allow sufficient time for development of immune protection prior to onset of influenza activity [1, 2] . During the past 18 years (excluding the pandemic influenza season of [2009] [2010] , the annual influenza season in the United States typically began in December or early January, as defined by the first week in which the number of influenza cases contributed ≥2% of cumulative influenza cases during the season among specimens tested by World Health Organization and US collaborating laboratories. However, early or late starts to the influenza season were not uncommon: In 3 seasons, the influenza season started by the beginning of December, and in 3 seasons, the influenza season started in or later than the third week of January. Duration of the annual influenza epidemic averaged about 13 weeks, with some seasons lasting as long as 17 weeks [3] .
Influenza vaccine is often available in the United States by the end of July [4] . The early availability of influenza vaccine and late arrival of the 2011-2012 influenza season prompted questions about the potential for intraseason waning of influenza vaccine effectiveness (VE). Several studies of influenza VE in Europe suggested that vaccinated persons more often presented later in the 2011-2012 season, an observation consistent with intraseason waning of influenza VE [5] [6] [7] [8] . Evidence for intraseason waning of effectiveness of the 2011-2012 southern hemisphere influenza vaccine was equivocal in Australia, which did not experience a late influenza epidemic that year [9] . In the following season (2012) (2013) in the United Kingdom, Andrews et al observed a pattern of lower VE with longer time since vaccination, but the finding was not statistically significant [10] . A pooled analysis of 5 recent influenza seasons in Europe found evidence of moderate waning of VE against influenza A(H3N2), mild waning of VE against influenza B, and no evidence of waning of VE against influenza A(H1N1)pdm09 virus infection [11] .
In this analysis, we examined the association between effectiveness of influenza vaccine and time since receipt of influenza vaccine among enrollees in the US Influenza VE Network case-control study of influenza VE for the 2011-2012 through 2014-2015 influenza seasons.
METHODS
The US Influenza Vaccine Effectiveness Network has been described previously [12, 13] . Adults and children seeking outpatient care for acute respiratory illnesses were enrolled at 5 locations in the United States (Seattle, Washington; Marshfield, Wisconsin; Southeast Michigan; Temple, Texas; and Pittsburgh, Pennsylvania) after influenza circulation was confirmed by local surveillance. Patients aged ≥6 months were eligible if they had illness with cough (in 2012-2013 through 2014-2015) or cough and/or fever/feverishness (in 2011-2012) of ≤7 days' duration. Consented patients were interviewed and provided throat and nasal swab specimens tested for influenza virus at Network laboratories with real-time reverse-transcription polymerase chain reaction (PCR) with primers, probes, and testing protocols provided by the US Centers for Disease Control and Prevention. In this "test-negative case-control" study, patients who tested positive for influenza were cases and patients who tested negative were the control group. Subjects were considered vaccinated if they had documented evidence in medical records or immunization registries of receipt of ≥1 dose of influenza vaccine for the current influenza season at least 14 days before illness onset.
Here, we examined the association between influenza VE and time since vaccination using data pooled from 4 influenza seasons and multivariate logistic regression models with PCRconfirmed outpatient influenza infection as the outcome and time between vaccination and symptom onset as the predictor. We excluded adults who received >1 dose of influenza vaccine in a given season and children ≤9 years of age to avoid difficulty introduced by receipt of 2 influenza vaccine doses at variable times within a single season. We excluded controls enrolled prior to the first case for each type/subtype-specific analysis. The analysis of VE against influenza A(H1N1)pdm09 excluded the 2014-2015 season, during which <5 cases were enrolled.
To examine variation in VE associated with time since vaccination rather than variation associated with any receipt of influenza vaccine, the model included both a term for receipt of influenza vaccine at any time at least 14 days prior to illness onset and a variable representing number of days between vaccination and illness onset specified as a natural cubic spline (details are shown in the Supplementary Data). We excluded subjects with vaccination between 0 and 13 days before illness onset for 2 reasons. First, immunologic studies suggest that 14 days is needed to mount an immune response to vaccination, and thus exposure status is effectively unknown during the period from 0 to 13 days after vaccination. Second, initial models that included subjects vaccinated 0-13 days prior to illness were unstable, with the direction of the spline unpredictable and contrary to the pattern suggested by studies of postvaccination antibody titers. To specify the spline representing time between vaccination and onset, we selected the number and placement of internal knots to maximize goodness of fit (by lowest Akaike information criterion) and best characterize the association between VE and time since vaccination assuming no functional form (Supplementary Data). If 2 or more splines fit the data equally well, we chose the more parsimonious. Unvaccinated individuals were the reference group. Variation in VE associated with time since vaccination was tested using a likelihood ratio test comparing a model including the spline terms representing time since vaccination and a dichotomous indicator of receipt of influenza vaccine receipt at any time at least 14 days prior to illness onset to a nested model excluding the spline terms. Because controls tended to have later onset than influenza A cases and earlier onset than influenza B cases, we restricted each pooled dataset to cases and 3-4 controls per case matched on onset date percentile (Supplementary Data). This restriction substantially improved balance between cases and controls on this confounding factor. Multivariate (unconditional) logistic regression models using the restricted datasets produced substantively similar results to models using exact case:control matching on onset date analyzed with conditional logistic regression and were preferred for computational ease.
We tested for 2-way interactions (effect modification) between time since vaccination and (i) age group and (ii) prior-season influenza vaccination status. Prior-season vaccination was defined as documented receipt of influenza vaccine in the immediately preceding influenza season. We examined the primary association for 3 time periods: the full study period, the earlier half of the study period (prior to and including the median influenza case onset date), and the latter half of the study period (after the median case onset date). In addition, we examined the association between influenza positivity and time since vaccination in models limited to vaccinees. To minimize misclassification of influenza status, study eligibility was limited to patients presenting to care within 7 days of illness onset and all eligible patients were tested by highly sensitive PCR. Analyses were conducted using R software version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria) and SAS software version 9.3 (Cary, North Carolina).
RESULTS
The number and temporal distribution of influenza cases varied substantially across the 4 seasons (study enrollment prior to dataset restriction is shown in Figure 1 ). Median case onset ranged from the first week of January in 2014-2015 to the first week of March in 2011-2012. After exclusions and restrictions, the pooled analytic datasets included 11 200 observations for analysis of VE against influenza A(H3N2), 4100 observations for analysis of VE against influenza A(H1N1)pdm09, and 5525 observations for analysis of VE against influenza B virus infection.
Age and sex distributions significantly differed for influenza cases and test-negative controls within each type/subtype analysis (Table 1) . Median subject age was 41 years in the influenza A analyses and 39 years in the influenza B analysis. Compared with influenza B cases, controls were older (P < .001). Compared with influenza cases of all type/subtypes, controls were more likely to be female (P < .05), to report poor health (P < .001), and to have received influenza vaccine (P ≤ .002). Median interval between vaccination and symptom onset was 95, 94, and 117 days for the influenza A(H3N2), A(H1N1)pdm09, and B virus analyses, respectively.
Adjusted VE against influenza A(H3N2) virus infection decreased with increasing time since vaccination, with maximum VE of 35% at 14 days postvaccination, and VE reaching zero at 158 days postvaccination (Figure 2A ; P = .004). Approximating this decline in VE as linear is equivalent to approximately a 7% (absolute) decline in VE per 30 days. Adjusted VE without including time since vaccination in the model was 24% (95% confidence interval [CI], 15%-32%). In a model limited to vaccinees, predicted risk of influenza A(H3N2) virus infection increased with time since vaccination ( Figure 2B ; P = .001).
Adjusted VE against influenza A(H1N1)pdm09 virus infection decreased with increasing time since vaccination, with maximum VE of 80% at 14 days postvaccination and minimum VE of 37% at 128 days postvaccination; estimated VE was 46% at 180 days postvaccination ( Figure 3A ; P = .01). Approximating this decline as linear is equivalent to a 6%-11% decline in VE per 30 days, comparing maximum observed VE to VE observed at 180 days postvaccination or to minimum observed VE, respectively. Adjusted VE without including time since vaccination in the model was 48% (95% CI, 36%-58%). In a model limited to vaccinees, predicted risk of influenza A(H1N1)pdm09 virus infection increased with time since vaccination ( Figure 3B ; P = .04).
Adjusted VE against influenza B virus infection decreased with increasing time since vaccination, with maximum VE of 59% at 14 days postvaccination and minimum VE of 23% at 180 days postvaccination ( Figure 4A ; P = .04). Approximating this decline as linear is equivalent to approximately a 7% decline in VE per 30 days. Adjusted VE without including time since vaccination in the model was 45% (95% CI, 33%-54%). In a model limited to vaccinees, predicted risk of influenza B virus infection increased with time since vaccination, but this result was not statistically significant ( Figure 4B ; P = .33). The observed decline in VE against influenza A(H3N2) virus infection with longer time since vaccination was more pronounced for subjects with onset later in the study period (P = .008 for interaction); however, this pattern was inconsistent across types/subtypes (Supplementary Figures 4-9 ). We observed no interaction between time since vaccination and age group for any type/subtype, although among subjects <60 years old there was a trend toward higher VE against influenza A(H1N1)pdm09 and lower VE against influenza B virus infection ( Supplementary  Figures 10-15 ). We observed an interaction between prior-season vaccination and time since vaccination for VE against each type/ subtype, with the decline in VE with increasing time since vaccination more pronounced among subjects with prior-season vaccination (P = .04, P = .006, and P = .01 for influenza A(H3N2), A(H1N1) pdm09, and B virus infection, respectively; Supplementary Figures  16-21 ). Season-specific results are presented in the Supplementary Data for seasons and influenza types/subtypes with at least 30 vaccinated cases (Supplementary Figures 22-27 ).
DISCUSSION
In combined data from 4 recent US influenza seasons, we observed a decrease in effectiveness of influenza vaccine with increasing time since vaccination for influenza A(H3N2), influenza A(H1N1)pdm09, and influenza B virus infections. Maximum VE was observed shortly after vaccination, followed by a decline in VE of about 7% per month for influenza A(H3N2) and influenza B and 6%-11% per month for influenza A(H1N1)pdm09 virus infections. VE remained greater than zero for at least 6 months for influenza A(H1N1)pdm09 and influenza B and at least 5 months for influenza A(H3N2) virus infection. This finding is similar to several reports that suggested waning effectiveness for the influenza A(H3N2) vaccine component observed in Europe, (20) 1860 (22) 268 (26) 687 (22) 249 (23) 935 (21) ≥65 510 (18) 1268 (15) 94 (9) 438 (14) 112 (10) 691 (16) Mean (SD) 42 (22) 41 (21) .75 41 (17) 41 (20) . although our results showed a somewhat less pronounced rate of decline. Unlike a recent study of 5 pooled European influenza seasons [11] , we observed similar rates of decline in VE across types/subtypes, including for VE against influenza B viruses. Our findings for influenza A(H3N2) viruses are consistent with those of Belongia et al [14] and Petrie et al [15] , who observed modest but detectable waning of influenza VE during the influenza A(H3N2)-predominant 2007-2008 US season. In our study, the observed decline in VE with longer time since vaccination was more pronounced among subjects with prior-season influenza vaccination. Human serologic studies suggest that repeat vaccination may blunt the antibody response to influenza vaccine [16] [17] [18] [19] , but the immunologic relationship between prior-and current-season vaccination and the influence of age and history of natural influenza infection on that relationship are poorly understood. Observational studies of repeat vaccination have demonstrated residual protection from influenza vaccination received more than a year prior [12, 13, 20] , consistent with a mild or moderate, but not pronounced, decline of vaccine protection over the course of an influenza season.
Studies of the serologic persistence of antibodies to influenza hemagglutinin among both elderly and healthy young adults found that seroprotection, if initially attained after vaccination, typically persisted for ≥4 months for the influenza A(H3N2) component of the vaccine [21] [22] [23] [24] [25] [26] . A person vaccinated early in a late-arriving influenza season could face an elapsed time of 6-7 months between vaccination and peak of influenza circulation, and there are too few studies to draw firm conclusions about persistence of host seroprotection over that time span. However, a randomized study of antibody persistence in healthy adults found that it took >58 weeks for geometric mean antibody titers to decrease 2-fold following vaccination with inactivated influenza vaccine [21] , and that this decrease in antibody titers was paralleled by a slow decrease in vaccine efficacy [15] . Overall, human serologic studies appear consistent with a modest rather than a sharp decline in influenza vaccine protection within a given season.
Alternative explanations for an observed decline in vaccine protection during an influenza season include emergence and circulation of a drifted variant less well-matched to the vaccine strain, as was observed in 2011-2012 in Europe, confounding by factors associated with both timing of vaccine receipt and likelihood of being influenza positive (for example, if cases presenting sooner after vaccination differ from other cases), bias introduced by changes in the composition of the at-risk population over the course of the season [27] [28] [29] , and bias arising from the so-called leaky vaccine effect [30, 31] . With the latter 2 situations, there may appear to be a decline in vaccine protection because unvaccinated individuals, who have a higher risk for infection (assuming vaccine confers at least some benefit), become infected and exit the at-risk population sooner, leaving proportionally more vaccinated individuals in the at-risk population over the course of the season, ultimately leading to vaccinated cases being overrepresented later in the season. Bias due to heterogeneity of the at-risk population and the leaky vaccine effect cannot be ruled out as causes of the decline in VE that we observed; however, models restricted to vaccinees, in which these biases would be expected to be less pronounced, gave similar results.
Although we attempted to control for characteristics associated with a tendency to be vaccinated earlier (such as age and presence of underlying health conditions), it is possible that the observed pattern of decreasing vaccine protection arose from uncontrolled confounding. It was particularly challenging to control for calendar time, and the trend toward steeper decline in VE observed in the later study period may reflect residual confounding by time. Small sample sizes required that we pool data across influenza seasons, which could have obscured season-by-season differences and necessitated the use of percentile of onset date rather than calendar date of onset to adjust for calendar time. Finally, VE estimated at the extremes of the range of time since vaccination were sensitive to the choice of spline specifying time since vaccination. Typically, the spline function tended to slightly overestimate VE at the early end of the range and underestimate VE at the late end of the range. For this reason, values at the extremes should be interpreted with caution.
There is no established method for modeling the association between VE and time since vaccination, and how best to examine the question of duration of VE remains a challenge. One possibility is a trial in which vaccine recipients are randomized to receive vaccine at different points in time prior to influenza season, similar to a "step wedge" design [32] . However, even randomized trials can be prone to biases that give the illusion of waning VE in the absence of such a phenomenon [27, 30, 31] . A definitive observational study is unlikely to be feasible, given it would require a large cohort in which influenza VE is measured at multiple time points during a season with data sufficiently rich to describe time-varying influenza exposure patterns and allow discrimination between putative mechanisms of vaccine action (ie, all-or-none vs leaky vaccine models).
Influenza seasons vary considerably in length, severity, and arrival time, and although vaccine is now available earlier, there is little evidence that large numbers of people in the United States are getting vaccinated considerably earlier than has previously occurred [33] . Evidence for intraseason waning of influenza vaccine protection is growing but inconsistent [5-10, 13, 15] . The possibility of waning VE merits further investigation; however, the current uncertainty in its nature and magnitude makes drawing conclusions difficult and suggests that careful consideration of the risks and benefits of delaying vaccination is needed before contemplating changes to current vaccine recommendations.
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